Skip to main content

Table 1 Objectives

From: Beta-blockeRs tO patieNts with CHronIc Obstructive puLmonary diseasE (BRONCHIOLE) – Study protocol from a randomized controlled trial

Primary objective

 • Does metoprolol therapy up to 100 mg per day in addition to standard care reduce the rate of the composite measure of death, COPD exacerbations, or cardiovascular events at 1 year in patients with COPD and no diagnosed cardiovascular disease at baseline, compared with standard care only?

Secondary objectives

 • Does treatment with metoprolol at a target dose of 100 mg in addition to standard care reduce the 1-year risk of death (all-cause and cause-specific) in patients with COPD and no diagnosed cardiovascular disease at baseline, compared with standard care only?

 • Does treatment with metoprolol at a target dose of 100 mg in addition to standard care reduce the 1-year risk of cardiovascular events in patients with COPD and no diagnosed cardiovascular disease at baseline, compared with standard care only?

 • Does treatment with metoprolol at a target dose of 100 mg in addition to standard care reduce the 1-year risk of COPD exacerbations in patients with COPD and no diagnosed cardiovascular disease at baseline, compared with standard care only?

  1. Primary and secondary objectives of the BRONCHIOLE trial. COPD Chronic obstructive pulmonary disease
Back to article page

Trials

ISSN: 1745-6215